XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE MEASUREMENTS (Tables)
 6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of Liabilities Measured on Recurring Basis
The following table presents our assets and liabilities measured at fair value on a recurring basis at June 30, 2023:

  Fair Value Measurements at 
June 30, 2023
TotalQuoted
Prices
in Active
Markets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Assets:
ABTC restricted common shares$7,100,000 $— $7,100,000 $— 
Liabilities:
Ionic convertible debenture derivative$(600,000)$— $— $(600,000)
LINICO related derivative(3,278,162)— (3,278,162)— 
Haywood derivative(605,000)— (605,000)— 
GenMat derivative(3,303,172)— (3,303,172)— 
Total liabilities measured at fair value$(7,786,334)$— $(7,186,334)$(600,000)
The following table presents our liabilities at December 31, 2022, measured at fair value on a recurring basis:

  Fair Value Measurements at
December 31, 2022
TotalQuoted
Prices
in Active
Markets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Liabilities:
Ionic convertible debenture derivative$(420,000)$— $— $(420,000)
LINICO related derivative (6,053,162)— (6,053,162)— 
Haywood derivative(1,480,000)— (1,480,000)— 
GenMat derivative(6,592,638)— (6,592,638)— 
Total liabilities measured at fair value$(14,545,800)$— $(14,125,800)$(420,000)